Magnesium Sulfate in Acute Stroke: A Randomized Double-Blind Clinical Trial
Background: Administration of magnesium sulfate has neuroprotective effects and reduces infarct volume in animal models of stroke. Previous small clinical trials have reported beneficial effect of magnesium on the outcome in patients with stroke. This study was a randomized, placebo-controlled, doub...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2004-08-01
|
| Series: | Journal of Research in Medical Sciences |
| Online Access: | http://journals.mui.ac.ir/jrms/article/view/908 |
| _version_ | 1828736998101221376 |
|---|---|
| author | S A Mousavi J Ziaei M Saadatnia |
| author_facet | S A Mousavi J Ziaei M Saadatnia |
| author_sort | S A Mousavi |
| collection | DOAJ |
| description | Background: Administration of magnesium sulfate has neuroprotective effects and reduces infarct volume in animal models of stroke. Previous small clinical trials have reported beneficial effect of magnesium on the outcome in patients with stroke. This study was a randomized, placebo-controlled, double-blind study , investigated the benefit of magnesium sulfate the administration given intravenously as a neuroprotective. Methods: Patients who had cortical infarction in the middle cerebral artery territory (superior or inferior division) with moderate neurologic deficits (Orgogozo scale score greater than 30 and less than 70) and onset less than 24 hours were included. The patients were treated with magnesium sulfate (4gr stat and 1gr/hr) or placebo for 4 days and examined by a blind investigator. NIH Stroke Scale was obtained on admission and fifth day after stroke. Results: Eighteen patients were given treatment and nineteen patients were given placebo who demonstrated significant beneficial effects on the difference between NIH Stroke Scales on the day of admission and day 5 (3.16 ± 0.98 vs. 1.84 ± 1.06; p = 0.000 respectively). Conclusion: Intravenous magnesium sulfate had significant beneficial effect on acute phase of stroke patients and, as a result, may reduce duration of admission. Keywords: Stroke, Magnesium sulfate, Neuroprotective. |
| first_indexed | 2024-04-12T23:36:40Z |
| format | Article |
| id | doaj.art-3f3afe5ef24146db980904276ed65f32 |
| institution | Directory Open Access Journal |
| issn | 1735-1995 1735-7136 |
| language | English |
| last_indexed | 2024-04-12T23:36:40Z |
| publishDate | 2004-08-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Research in Medical Sciences |
| spelling | doaj.art-3f3afe5ef24146db980904276ed65f322022-12-22T03:12:07ZengWolters Kluwer Medknow PublicationsJournal of Research in Medical Sciences1735-19951735-71362004-08-0194158161Magnesium Sulfate in Acute Stroke: A Randomized Double-Blind Clinical TrialS A MousaviJ ZiaeiM SaadatniaBackground: Administration of magnesium sulfate has neuroprotective effects and reduces infarct volume in animal models of stroke. Previous small clinical trials have reported beneficial effect of magnesium on the outcome in patients with stroke. This study was a randomized, placebo-controlled, double-blind study , investigated the benefit of magnesium sulfate the administration given intravenously as a neuroprotective. Methods: Patients who had cortical infarction in the middle cerebral artery territory (superior or inferior division) with moderate neurologic deficits (Orgogozo scale score greater than 30 and less than 70) and onset less than 24 hours were included. The patients were treated with magnesium sulfate (4gr stat and 1gr/hr) or placebo for 4 days and examined by a blind investigator. NIH Stroke Scale was obtained on admission and fifth day after stroke. Results: Eighteen patients were given treatment and nineteen patients were given placebo who demonstrated significant beneficial effects on the difference between NIH Stroke Scales on the day of admission and day 5 (3.16 ± 0.98 vs. 1.84 ± 1.06; p = 0.000 respectively). Conclusion: Intravenous magnesium sulfate had significant beneficial effect on acute phase of stroke patients and, as a result, may reduce duration of admission. Keywords: Stroke, Magnesium sulfate, Neuroprotective.http://journals.mui.ac.ir/jrms/article/view/908 |
| spellingShingle | S A Mousavi J Ziaei M Saadatnia Magnesium Sulfate in Acute Stroke: A Randomized Double-Blind Clinical Trial Journal of Research in Medical Sciences |
| title | Magnesium Sulfate in Acute Stroke: A Randomized Double-Blind Clinical Trial |
| title_full | Magnesium Sulfate in Acute Stroke: A Randomized Double-Blind Clinical Trial |
| title_fullStr | Magnesium Sulfate in Acute Stroke: A Randomized Double-Blind Clinical Trial |
| title_full_unstemmed | Magnesium Sulfate in Acute Stroke: A Randomized Double-Blind Clinical Trial |
| title_short | Magnesium Sulfate in Acute Stroke: A Randomized Double-Blind Clinical Trial |
| title_sort | magnesium sulfate in acute stroke a randomized double blind clinical trial |
| url | http://journals.mui.ac.ir/jrms/article/view/908 |
| work_keys_str_mv | AT samousavi magnesiumsulfateinacutestrokearandomizeddoubleblindclinicaltrial AT jziaei magnesiumsulfateinacutestrokearandomizeddoubleblindclinicaltrial AT msaadatnia magnesiumsulfateinacutestrokearandomizeddoubleblindclinicaltrial |